...ALK (D5F3) were negative. High-throughput sequencing detected MTOR gene mutations in 6 cases, while non-mTOR pathway-rel...
...ALK inhibitor to show a consistent DFS benefit over chemotherapy in patients with resected early-stage ALK-positive NSCL...
...ALK (50–60%), ROS1 (5–10%), and less commonly NTRK3 or RET. We report a 32-year-old woman with an unresectable pulmonary...
...ALK C1156Y mutation in another. Selection of the appropriate drug was carried out using molecular docking simulations, w...
...ALK(IVS19..END) fusion; ALK protein expression was confirmed by immunohistochemistry (IHC). Ensartinib 225 mg orally onc...
...ALK-, BRAFV600E-) and staging excluded systemic disease. The patient remained hemodynamically stable and was managed con...
...ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior ALK tyrosine kinas...
...ALK, BRAF, and MET were identified using targeted NGS panels. Smoking exposure and duration of U.S. residence were summa...
...ALK inhibitors like alectinib, brigatinib and lorlatinib lower the incidence of BM. In HER2-positive breast cancer, tuca...
...ALK) rearranged non-small cell lung cancer (NSCLC), also combined with a progressively better safety profile, from chemo...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2026.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
